Showing results (391-400 of 422) with videos related to

Sort By:
Pageof 43
Clinical and Translational Allergy|November 10, 2016
Standardization of double blind placebo controlled food challenge with soy within a multicentre trialR Treudler, A Franke, A Schmiedeknecht, et al.
Allergy|July 4, 2017
Meat allergy associated with galactosyl-α-(1,3)-galactose (α-Gal)-Closing diagnostic gaps by anti-α-Gal IgE immune profilingU Jappe, S Minge, B Kreft, et al.
Allergy|November 21, 2013
Management of anaphylaxis: a systematic reviewS Dhami, S S Panesar, G Roberts, et al.
Allergy|February 21, 2013
Evaluation of commercial skin prick test solutions for selected occupational allergensV van Kampen, F de Blay, I Folletti, et al.
Cellular and Molecular Life Sciences : CMLS|October 15, 2011
Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, GermanyM Peiser, T Tralau, J Heidler, et al.
Journal of the American Chemical Society|July 8, 2014
Reversible CO binding enables tunable CO/H₂ and CO/N₂ separations in metal-organic frameworks with exposed divalent metal cationsEric D Bloch, Matthew R Hudson, Jarad A Mason, et al.
Arthritis Care & Research|June 1, 2019
Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic SclerosisD Belz, P Moinzadeh, G Riemekasten, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|September 8, 2018
[Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany]E Haufe, S Abraham, A Heratizadeh, et al.
Breast Cancer Research and Treatment|May 9, 2014
Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testingPriyanka Sharma, Jennifer R Klemp, Bruce F Kimler, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
Pageof 43